Hairy Cell Leukemia Treatment Approved.
The FDA approved moxetumomab pasudotox-tdfk, a CD22-directed recombinant immunotoxin, for patients with relapsed/refractory hairy cell leukemia who have not responded to at least two prior treatments, including a purine nucleoside analogue.